This grant is for advancing fundamental research into diffuse white matter disease (DWMD), a highly prevalent condition in the elderly clinically linked to vascular contributions to cognitive impairment and dementia (VCID). DWMD involves pathologies like demyelination, fiber loss, and local ischemia. Despite its significance, major knowledge gaps persist regarding DWMD’s cellular and molecular causes, regional vulnerability, progression over time, and its physiological consequences on axon and neural circuit function. The purpose is to address these critical gaps by exploring the biologic mechanisms of this common cerebrovascular and age-related disease at molecular, cellular, tissue, and brain circuit levels. This research ultimately aims to inform future strategies to reduce the burden of illness caused by age-related VCID.
Opportunity ID: 353430
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-196 |
| Funding Opportunity Title: | Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 – Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 05, 2024 |
| Last Updated Date: | Apr 05, 2024 |
| Original Closing Date for Applications: | Oct 04, 2024 |
| Current Closing Date for Applications: | Oct 04, 2024 |
| Archive Date: | Nov 09, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education Small businesses Native American tribal organizations (other than Federally recognized tribal governments) County governments Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Native American tribal governments (Federally recognized) Independent school districts State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | (Reissue of RFA-NS-16-021, PAR-18-413, RFA-NS-19-039) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or cerebellum. Though most commonly extending out from the periventricular surfaces, it may also occur in subcortical white matter. Diffuse white matter disease is typically detected in clinical settings as hyperintensity on magnetic resonance imaging (MRI) or signal loss on computed tomography x-ray (CT) scan; diffuse white matter disease can be detected histologically as well, for example in human pathology and in studies using animal models. Despite the prevalence and potential significance of white matter disease for cerebrovascular disease etiology and cognitive outcomes, much remains to be learned about the cellular and molecular causes, regional vulnerability, and progression over time. The physiological consequences of diffuse white matter disease on local axon and neural circuit function are almost completely unknown. The purpose of this FOA is to address some of the many gaps in knowledge of the biologic mechanisms of the commonly occurring, cerebrovascular disease and age-related diffuse white matter disease at the molecular, cellular, tissue and brain circuit level. The ultimate goal of this fundamental research is to inform future efforts to reduce the burden of illness due to age-related vascular contributions to cognitive impairment and dementia. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-196.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 353430 Full Announcement-PAR-24-196 -> PAR-24-196-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00285769 | Sep 04, 2024 | Oct 04, 2024 | View |
Package 1
Mandatory forms
353430 RR_SF424_5_0-5.0.pdf
353430 PHS398_CoverPageSupplement_5_0-5.0.pdf
353430 RR_OtherProjectInfo_1_4-1.4.pdf
353430 PerformanceSite_4_0-4.0.pdf
353430 RR_KeyPersonExpanded_4_0-4.0.pdf
353430 PHS398_ResearchPlan_5_0-5.0.pdf
353430 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
353430 RR_Budget_3_0-3.0.pdf
353430 RR_SubawardBudget30_3_0-3.0.pdf
353430 PHS398_ModularBudget_1_2-1.2.pdf
353430 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
